AAP
RAPT

Arax Advisory Partners’s RAPT Therapeutics RAPT Stock Holding History

Arax Advisory Partners’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$25 – 4444
2025
Q3 		$25 Buy
+1
New +$13 ﹤0.01% 3568

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Arax Advisory Partners's RAPT Position: Q4 2025 in Review

Arax Advisory Partners sold out of RAPT Therapeutics (RAPT) in Q4 2025, closing a stake of 1 share — an estimated $25 sold.

Arax Advisory Partners first reported a position in RAPT in Q3 2025 and held it in 1 quarter. The position peaked at $25 in Q3 2025. 105 funds tracked by Wall St. Rank hold RAPT as of Q4 2025.

  • Arax Advisory Partners reported no remaining RAPT Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 1 RAPT Therapeutics share in Q4 2025, an estimated $25.
  • Arax Advisory Partners first reported a position in RAPT Therapeutics in Q3 2025 and held it in 1 quarter.
  • Arax Advisory Partners's RAPT Therapeutics position peaked at $25 in Q3 2025.
  • 105 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.